All articles from EyeWorld.org on the topic of cataract surgery. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ CRISPR gene-editing trial shows ‘exciting potential’ ➤ Study: laser vision correction clinics missing opportunities ➤ Broad-based protection observed with investigational geographic atrophy therapy ➤ FDA accepts IND for diabetic macular edema therapy ➤ Phase 2 trial for non-proliferative diabetic retinopathy therapy does not meet primary endpoint ➤ ASCRS news and events
➤ FDA clears fully autonomous, portable AI device for diabetic retinopathy screening ➤ Positive preliminary data for Phase 1/2 trial evaluating gene therapy treatment for X-linked retinoschisis ➤ Dosing in Phase 1/2 trial for allogenic cell therapy for corneal edema ➤ Dosing complete in trial assessing corneal edema therapy ➤ Phase 4 results for mydriasis product reported ➤ Collaboration seeks to commercialize Alzheimer’s detection through retinal imaging ➤ ASCRS news and events
➤ Topline results for investigational diabetic retinopathy therapy ➤ Dosing complete in second cohort for Phase 1/2 trial for geographic atrophy therapy ➤ Large data modules launched for dry eye disease and thyroid eye disease ➤ Study: Real-world outcomes of MIGS combined with cataract surgery vs. cataract surgery alone ➤ ASCRS news and events
➤ Phase 3 results for new corticosteroid ➤ Positive topline results from Phase 3 trials investigating presbyopia drop ➤ Phase 2 data presented for IOP-lowering intracameral implant ➤ First patient dosed in retinitis pigmentosa gene therapy ➤ Survey shows burden of pterygium ➤ ASCRS news and events
➤ Positive topline results in trial for retinitis pigmentosa treatment ➤ Phase 2 trial for first-in-human inflammatory dry eye therapy ➤ Landmark clinical trial shows non-inferiority of Nanodropper technology ➤ Dosing complete for gene therapy aiming to help patients with Leber congenital amaurosis ➤ Enrollment begins for secondary IOL technology Phase 1 pivotal trial ➤ Strategic alignment news ➤ ASCRS news and events
➤ Phase 3 clinical trial for water-free dry eye cyclosporine drop ➤ Phase 2b results for drug-eluting contact lens for glaucoma ➤ Dosing continues for Phase 1/2 trial evaluating gene therapy for X-linked retinoschisis ➤ Higher dose, extended wet AMD treatment non-inferior to standard of care ➤ Study: AI detects severe retinopathy of prematurity with 100% accuracy ➤ Complimentary access to video journal ➤ ASCRS news and events
David F. Chang, MD, will deliver the Charles D. Kelman, MD, Innovator’s Lecture during the ASCRS Annual Meeting. Dr. Chang’s lecture will introduce the concept of “frugal innovation,” which involves coming up with ways to deliver quality care either less expensively or by using fewer resources.
➤ Study: artificial intelligence matches/outperforms ophthalmologists ➤ Primary endpoint met in Phase 3 trial using an antibody to treat thyroid eye disease ➤ FDA grants Breakthrough Device Designation to novel spectacle design ➤ ASCRS news and events
➤ FDA approves first IND for RNA exon editor ➤ SPA granted for Phase 3 trial of an intravitreal implant for wet AMD ➤ Study: retinal imaging helps predict risk of developing a host of diseases ➤ European Medicines Agency recommends rejection of pegcetacoplan for GA ➤ ASCRS news and events
➤ FDA agrees to special protocol assessment for AMD clinical trial ➤ Topline data from Phase 2 trial evaluating suprachoroidal wet AMD treatment ➤ First patient dosed in Phase 1 DME treatment study ➤ Study: new gene variants contributing to glaucoma susceptibility identified ➤ ASCRS news and events